-
Check the chart of your next patient. She says she has vaginal itching and irritation, odor, and vaginal discharge. What is your next step?
-
The Food and Drug Administration (FDA) has ruled out mifepristone (Mifeprex, Danco Laboratories, New York City) as the cause in one of two recent deaths of women who had taken the drug. The agency is continuing to investigate the other death.
-
When it comes to sexually transmitted diseases (STDs), new data released by the American Social Health Association (ASHA) in Research Triangle Park, NC, shows that the average age of people who are tested for chlamydia is 28.9 for women and 30.5 for men.
-
Early research in rhesus monkeys indicates that a combination of two AIDS treatment drugs, tenofovir (TDF, Viread, Gilead; Foster City, CA) and emtricitabine (FTC, Emtriva; Gilead), may be effective in HIV prevention.
-
Call it "crystal," "tina," or "crank," use of crystal methamphetamine is cutting across all socioeconomic and sexual boundaries. How does that affect your family planning facility?
-
-
Does the condom program at your clinic consist of filling a bowl with one style of condoms in the waiting room? If so, you may want to rethink your strategy.
-
A new analysis indicates that the prevalence of herpes simplex virus Type 2 (HSV-2) is dropping in the United States.
-
The Centers for Disease Control and Prevention (CDC) is recommending that voluntary HIV screening become a routine part of medical care for all patients ages 13 to 64.
-
Take a look around your family planning facility staff. Are there many new hires, or is the landscape comprised of seasoned veterans?